Research progress on activated leukocyte adhesion molecules in lupus nephritis

doi:10.3969/j.issn.1006-7795.2025.01.023

Journal of Capital Medical University ›› 2025, Vol. 46 ›› Issue (1): 150-153.doi: 10.3969/j.issn.1006-7795.2025.01.023

Previous Articles Next Articles

Research progress on activated leukocyte adhesion molecules in lupus nephritis

Weng Kexia¹, Li Bing^1，2，3*

1.Nephrology Department, the Second Affiliated Hospital Clinical College of Hainan Medical University, Haikou 571199, China; 2.Nephroglogy of Institute, the Second Affiliated Hospital, Hainan Medical University; Hainan Clinical Research Center for Urinary System Diseases, Haikou 570216, China; 3. National Health Commission of China, Key Laboratory of Tropical Disease Control, School of Tropical Medicine, Hainan Medical University, Haikou 571199, China

Received:2024-05-30 Online:2025-02-21 Published:2025-02-25
Supported by:
This study was supported by National Natural Science Foundation of China (82370697), Clinical Medical Research Center Project in Hainan Province (LCYX202409), Research of Molecular Epidemiology and Development of Prevention & Control Technology for Tropical Disease (2020-PT310-009).

Abstract

Abstract: Lupus nephritis (LN) is a common and serious complication of systemic lupus erythematosus(SLE). The clinical course of LN is usually characterized by alternating phases of remission and exacerbation. The onset of LN can lead to deterioration of renal function and requires prompt diagnosis and treatment. Some studies have suggested that the presence and changes of activated leukocyte cell adhesion molecule (ALCAM) may be related to the development of LN as well as LN activity. Urinary activated leukocyte cell adhesion molecule (uALCAM) is promising as a non-invasive marker for evaluating LN activity in SLE patients. Determination of uALCAM levels is helpful in early diagnosis, indication of disease activity and prediction of disease recurrence. ALCAM is expressed in a variety of cells and exerts different biological effects, including regulating cell differentiation, proliferation and migration. It is also pathologically expressed in various malignant tumors and has carcinogenic properties.This review will review the existing research on the role of ALCAM in the genesis and progression of LN, and the potential role of ALCAM as a new diagnostic marker and therapeutic target.

Key words: lupus nephritis, activated leukocyte cell adhesion molecule, biomarkers, therapeutic targets

CLC Number:

R593

Weng Kexia, Li Bing. Research progress on activated leukocyte adhesion molecules in lupus nephritis[J]. Journal of Capital Medical University, 2025, 46(1): 150-153.

0
/ Save 0 / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2025.01.023

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2025/V46/I1/150

References

［1］ Zhao Y, Wei W, Liu M L. Extracellular vesicles and lupus nephritis—new insights into pathophysiology and clinical implications［J］. J Autoimmun, 2020, 115: 102540.
［2］ Boeltz S, Hagen M L I, Knopf J, et al. Towards a pro-resolving concept in systemic lupus erythematosus［J］. Semin Immunopathol, 2019, 41(6): 681－697.
［3］ Mohan C, Zhang T, Putterman C. Pathogenic cellular and molecular mediators in lupus nephritis［J］. Nat Rev Nephrol, 2023, 19(8): 491－508.
［4］张凯聪. 狼疮性肾炎生物标志物［J］. 肾脏病与透析肾移植杂志, 2018, 27(5): 463－467.
［5］ Chalmers S A, Ayilam Ramachandran R, Garcia S J, et al. The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses［J］. J Clin Invest, 2022, 132(1): e147334.
［6］ Allison S. ALCAM-CD6 in lupus nephritis［J］. Nat Rev Nephrol, 2022, 18(3): 137.
［7］ Ferragut F, Vachetta V S, Troncoso M F, et al. ALCAM/CD166: a pleiotropic mediator of cell adhesion, stemness and cancer progression［J］. Cytokine Growth Factor Rev, 2021, 61: 27－37.
［8］ Yang Y M, Sanders A J, Dou Q P, et al. The clinical and theranostic values of activated leukocyte cell adhesion molecule (ALCAM)/CD166 in human solid cancers［J］. Cancers (Basel), 2021, 13(20): 5187.
［9］ Gilsanz A, Sánchez-Martín L, Gutiérrez-López M D, et al. ALCAM/CD166 adhesive function is regulated by the tetraspanin CD9［J］. Cell Mol Life Sci, 2013, 70(3): 475－493.
［10］ Hebron K E, Li E Y, Arnold Egloff S A, et al. Alternative splicing of ALCAM enables tunable regulation of cell-cell adhesion through differential proteolysis［J］. Sci Rep, 2018, 8(1): 3208.
［11］ Hassan N J, Barclay A N, Brown M H. Frontline: optimal T cell activation requires the engagement of CD6 and CD166［J］. Eur J Immunol, 2004, 34(4): 930－940.
［12］ Mayadas T N, Tsokos G C, Tsuboi N. Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury［J］. Circulation, 2009, 120(20): 2012－2024.
［13］ Kyttaris V C, Tsokos G C. Targeting lymphocyte signaling pathways as a therapeutic approach to systemic lupus erythematosus［J］. Curr Opin Rheumatol, 2011, 23(5): 449－453.
［14］ Koga T, Ichinose K, Tsokos G C. T cells and IL-17 in lupus nephritis［J］. Clin Immunol, 2017, 185: 95－99.
［15］ Paredes J L, Fernandez-Ruiz R, Niewold T B. T cells in systemic lupus erythematosus［J］. Rheum Dis Clin North Am, 2021, 47(3): 379－393.
［16］ Zimmerman A W, Joosten B, Torensma R, et al. Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells［J］. Blood, 2006, 107(8): 3212－3220.
［17］ Masedunskas A, King J A, Tan F, et al. Activated leukocyte cell adhesion molecule is a component of the endothelial junction involved in transendothelial monocyte migration［J］. FEBS Lett, 2006, 580(11): 2637－2645.
［18］ Sulaj A, Kopf S, Gröne E, et al. ALCAM a novel biomarker in patients with type 2 diabetes mellitus complicated with diabetic nephropathy［J］. J Diabetes Complications, 2017, 31(6): 1058－1065.
［19］ von Bauer R, Oikonomou D, Sulaj A, et al. CD166/ALCAM mediates proinflammatory effects of S100B in delayed type hypersensitivity［J］. J Immunol, 2013, 191(1): 369－377.
［20］ Lécuyer M A, Saint-Laurent O, Bourbonnière L, et al. Dual role of ALCAM in neuroinflammation and blood-brain barrier homeostasis［J］. Proc Natl Acad Sci U S A, 2017, 114(4): E524－E533.
［21］ Breuning J, Brown M H. T cell costimulation by CD6 is dependent on bivalent binding of a GADS/SLP-76 complex［J］. Mol Cell Biol, 2017, 37(11): e00071－17.
［22］ Stanley S, Vanarsa K, Soliman S, et al. Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities［J］. Nat Commun, 2020, 11(1): 2197.
［23］ Hedberg A, Mortensen E S, Rekvig O P. Chromatin as a target antigen in human and murine lupus nephritis［J］. Arthritis Res Ther, 2011, 13(2): 214.
［24］ Ding H, Lin C, Cai J, et al. Urinary activated leukocyte cell adhesion molecule as a novel biomarker of lupus nephritis histology［J］. Arthritis Res Ther, 2020, 22(1): 122.
［25］ Smith E M D, Jorgensen A L, Midgley A, et al. International validation of a urinary biomarker panel for identification of active lupus nephritis in children［J］. Pediatr Nephrol, 2017, 32(2): 283－295.
［26］ Lei R W, Thai N, Li Y X, et al. Analytical validation of urine ALCAM ELISA as a test for lupus nephritis［J］. Expert Rev Mol Diagn, 2023, 23(8): 729－738.
［27］ Parodis I, Gokaraju S, Zickert A, et al. ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus［J］. Rheumatology (Oxford), 2020, 59(9): 2237－2249.
［28］ Soliman S A, Haque A, Vanarsa K, et al. Urine ALCAM,PF4 and VCAM-1 surpass conventional metrics in identifying nephritis disease activity in childhood-onset systemic lupus erythematosus［J］. Front Immunol, 2022, 13: 885307.
［29］ Phillips R. CD6 is a therapeutic target for LN［J］. Nat Rev Rheumatol, 2022, 18(3): 125.

Research progress on activated leukocyte adhesion molecules in lupus nephritis

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 1

Recommended Articles 0

Metrics

Comments